Should You Buy Gohealth Inc (GOCO) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Sell
Latest Price
2.200
1 Day change
2.80%
52 Week Range
21.000
Analysis Updated At
2026/01/28
GOCO is not a good buy right now for a beginner long-term investor with $50k–$100k who doesn’t want to wait for an “ideal” setup. The stock is in a clear downtrend (bearish moving averages) and the business fundamentals deteriorated sharply in the latest reported quarter, while Wall Street sentiment has recently moved more negative via downgrades and major price-target cuts. With no near-term catalysts and no proprietary buy signals today, the risk/reward is unfavorable versus simply allocating capital to higher-quality long-term names.
Technical Analysis
Trend: Bearish. The moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend.
Momentum: MACD histogram is slightly positive (0.00495) but “positively contracting,” which usually means any rebound momentum is weak and fading rather than strengthening.
RSI: RSI_6 at ~32 is near oversold territory but still labeled neutral here—this can support short bounces, but it does not override the broader downtrend.
Levels: Price ~2.14 is sitting just below S1 (2.165) and above S2 (2.059). If 2.059 breaks, downside risk increases. Key upside hurdles are Pivot 2.337, then R1 2.509.
Pattern-based odds: Similar-pattern study suggests only modest expected gains (about +0.58% next week; +5.92% next month), which is not compelling given the fundamental deterioration.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
- Potential longer-term upside if Medicare Advantage market conditions stabilize and carriers resume more aggressive growth posture.
- One analyst (Noble Capital) still references attractive long-term revenue/margin potential after market normalization.
- Hedge funds and insiders show neutral activity (no strong recent selling signal from these groups in the provided data).
Neutral/Negative Catalysts
- Event-driven headwind cited by analysts: topline weakness tied to a large carrier suspending its relationship (directly pressured results and outlook).
- No positive news flow in the most recent week (no near-term catalyst support).
- Technical setup remains bearish with price near support levels, implying elevated risk of another leg down if support fails.
Financial Performance
Latest quarter: 2025/Q3. Results show severe deterioration:
- Revenue: $34.186M, down -71.10% YoY.
- Net Income: -$166.835M, down -2950.91% YoY (loss expanded dramatically).
- EPS: -11.8, down -2665.22% YoY.
- Gross Margin: -27.56% (negative), down -143.42% YoY.
Overall: This is a sharp contraction in scale and profitability in Q3 2025, reinforcing a weak fundamental backdrop for a long-term “buy now” decision.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Ratings and targets have moved materially more bearish.
- 2025-11-26: RBC Capital cut PT to $5 from $12; kept Sector Perform, citing Q3 significantly below expectations and carrier relationship disruption.
- 2025-11-18: William Blair downgraded to Market Perform from Outperform, citing market headwinds likely through 2026, uncertainty around sustainable positive cash flow, and limited diversification progress.
- 2025-11-14: Noble Capital cut PT to $10 from $20 but maintained Outperform, arguing long-term potential once the Medicare Advantage market stabilizes.
Wall Street pros vs cons:
Pros: Some belief in longer-term operating potential after industry stabilization.
Cons (dominant right now): Major estimate resets, prolonged headwinds into 2026, cash-flow sustainability concerns, and customer/carrier concentration risk highlighted by the carrier suspension.
Wall Street analysts forecast GOCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOCO is 7.5 USD with a low forecast of 5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast GOCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOCO is 7.5 USD with a low forecast of 5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.140
Low
5
Averages
7.5
High
10
Current: 2.140
Low
5
Averages
7.5
High
10
RBC Capital
Sector Perform
downgrade
$12 -> $5
AI Analysis
2025-11-26
Reason
RBC Capital
Price Target
$12 -> $5
AI Analysis
2025-11-26
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on GoHealth to $5 from $12 and keeps a Sector Perform rating on the shares. The firm is updating its model following the company's Q3 results, which came in significantly below expectations due to topline weakness as a result of one large carrier suspending its relationship with, the analyst tells investors in a research note.
William Blair
Outperform -> Market Perform
downgrade
2025-11-18
Reason
William Blair
Price Target
2025-11-18
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded GoHealth to Market Perform from Outperform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GOCO
